The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...
Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...
When Galapagos and Gilead Sciences entered a global drug R&D collaboration six years ago, the deal focused on Galapagos’s ...
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its current workforce.
It was a busy week for the biotech sector with updates from quite a few players. While pharma bigwig Amgen (NASDAQ:AMGN) agreed to buy Celgene’s (NASDAQ:CELG) Otezla, ...
The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.
Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty payments to Gilead on the sales of certain products.
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.